Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2011

View Archived Issues

Phase III briakinumab data analyzed

Scientists at Astellas Pharma synthesize novel plasma kallikrein inhibitors

Phase II studies assess NGR-hTNF in lung and ovarian cancer

Novel TRPV4 antagonists prepared by researchers at GlaxoSmithKline

Phase III trial of cabozantinib meets primary endpoint

RetroSense Therapeutics licenses gene therapy from Wayne State University

EMA begins new review of Protelos and Osseor

Qutenza shows efficacy in HIV-associated neuropathy

New data presented from CARE-MS trials of alemtuzumab

Novel omega-3 MUFAs show oncolytic potential

Precision Antibody receives FDA contract to develop potency assays for influenza vaccine

TiGenix moves into randomized recruitment stage in phase Ia/IIb Cx-611 study

Merck Frosst discloses new HIV reverse transcriptase inhibitors

California Stem Cell acquires stem cell therapy program for metastatic melanoma

Basilea finishes multiple-ascending-dose study of antibiotic BAL-30072

Italian researchers prepare novel TRPV1 antagonists

New glucagon receptor antagonists designed by Merck & Co.

CDC advisory committee recommends Merck & Co.'s HPV vaccine for boys and young men

Lilly withdraws Xigris worldwide following PROWESS-SHOCK study

Bayer's phase III CORRECT trial meets primary endpoint

Elusys initiates new human safety study of anthrax treatment candidate

FDA provides update on safety review of Chantix

FDA grants IND clearance for phase II trial of Aeterna Zentaris' AEZS-108 in breast cancer

Seattle Genetics starts new Adcetris trial in nonlymphoma malignancies

DelMar Pharmaceuticals commences phase I/II trial of VAL-083

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...